Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 27Gastrointestinal 15Tumor-Agnostic 5Thoracic 5Lymphoid 5Head & Neck 5Genitourinary 5Other hematologic neoplasm 4CNS 4Plasma cell 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Breast 1

Conditions

Neoplasms 3Neoplasms by Site 1Carcinoma 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × relatlimab × Tumor-Agnostic × Clear all
NCT03899155 2026-06-03

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT05347212 2026-04-15

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
Tumor-Agnostic

Carcinoma

NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
1,482 enrolled 56 charts
Tumor-Agnostic

Neoplasms by Site

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡